SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia Options Price in $280 Billion Earnings Swing 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Trump Buys SpaceX Shares After Record IPO 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
SHANGHAI, China, April 24, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:30am ET to discuss financial results for the full year ended December 31, 2017. On the call, Zai Lab’s senior management team will also provide the latest status update on the Company’s various development programs.
Investor Conference Call Details
Date: Wednesday, May 2nd, 2018
Time: 8:30am ET
Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)
Conference ID: 5836799
A live webcast and replay will be available on the Zai Lab investor website: http://ir.zailaboratory.com. Please note, on Monday, April 30th, 2018 Zai Lab intends to file its Form 20-F for the Year Ended December 31, 2017.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
Contact:
Zai Lab
Billy Cho
+86 137 6151 2501
[email protected]
Solebury Trout
John Graziano
+1 646 378 2942
[email protected]
